Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma

European Journal of Nuclear Medicine

Volumn 25, Issue 11, 1998, Pages 1482-1488

  Bernà, Lluís ^a   Chico, Ana ^a   Matías Guiu, Xavier ^a   Mato, Eugenia ^a   Catafau, Ana ^a   Alonso, Carmen ^a   Mora, Josefina ^a   Mauricio, Didac ^b   Rodríguez Espinosa, José ^a   Mari, Carina ^a   Flotats, Albert ^a   Martín, Juan Carlos ^a   Estorch, Montserrat ^a   Carrió, Ignasi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL DE SABADELL   (Spain)

Author keywords

111In octreotide; Medullary thyroid carcinoma; Octreoscan

Indexed keywords

INDIUM 111; OCTREOTIDE; PENTETREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; FEMALE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECURRENT DISEASE; REOPERATION; SARCOIDOSIS; THYROID MEDULLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

ADULT; AGED; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; FEMALE; HORMONE ANTAGONISTS; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 15644376162     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050325     Document Type: Article

References (29)

1. Graze K, Spiler IJ, Tashjian AH Jr, et al. Natural history of familial medullary thyroid carcinoma: effect of a program for early diagnosis. N Engl J Med 1978; 299: 980-985.
2. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. Medicine 1984; 63: 319-342.
3. Grauer A, Raue F, Gagel R. Changing concepts in the management of hereditary and sporadic medullary carcinoma. Endocrinol Metab Clin North Am 1990; 19: 613-635.
4. Hoefnagel CA, Delprat CC, Zanin D, Vand Der Schoot JB. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 1988; 13: 159-165.
5. 99mTc MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988; 29: 33-38.
6. Guerra UP, Pizzocaro C, Terzi A, et al. New tracers for the imaging of the medullary thyroid carcinoma. Nucl Med Commun 1989; 10: 285-295.
7. Mrad MDB, Gardet P, Roche A, et al. Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer 1989; 63: 133-138.
8. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-1249.
9. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76: 1413-1417.
10. Krausz Y, deJong RBJ, Glaser B. Somatostatin-receptor scintigraphy of endocrine tumors. J Nucl Med 1993; 34 (Suppl): 164P.
11. Dörr U, Frank-Raue K, Raue F, et al. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 1993; 14: 439-445.
12. Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995; 42: 31-37.
13. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatinrezeptorzintigraphie bei medullären Schilddrüsenkarzinomen, GEP-Tumoren und Karzinoiden. Nucl Med 1995; 34: 1-7.
14. 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 1995; 144: 339-345.
15. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-916.
16. O'Byrne KJ, O'Hare N, Sweeney E, Freyne PJ, Cullen MJ. Somatostatin and somatostatin analogues in medullary thyroid carcinoma. Nucl Med Commun 1996; 17: 810-816.
17. Behr TM, Gratz S, Markus PM, et al. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Eur J Nucl Med 1997; 24: 184-191.
18. Tisell LE, Ahlman H, Wängberg B, et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997; 84: 543-547.
19. Pacini E, Elisei R, Anelli S, Basolo F, Cola A, Pinchera A. Somatostatin in medullary thyroid cancer. In vitro and in vivo studies. Cancer 1989; 63: 1189-1195.
20. Mahler C, Verhelst J, de Longueville M, Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 1990; 33: 261-269.
21. Chomcynsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
22. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80: 1386-1392.
23. Schroeder S, Bocker W, Baiseh H, et al. Prognostic factors in medullary thyroid carcinomas: survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 1988; 61: 806-816.
24. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987; 14: 343-353.
25. Samaan NA, Schultz, PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988; 67: 801-805.
26. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press; 1995: 1-50.
27. Fischman AJ, Babich JW. Radiolabeled peptides: a new class of imaging agents. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press; 1997: 103-131.
28. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-573.
29. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann NY Acad Sci 1994; 733: 138-146.